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Abstract
Oncostatin M receptor (OSMR) is commonly over-expressed in advanced cervical squamous cell carcinoma (SCC),
producing a significantly worse clinical outcome. Cervical SCC cells that over-express OSMR show enhanced
responsiveness to the major ligand OSM, which induces multiple pro-malignant effects, including increased cell
migration and invasiveness. Here, we show that tissue transglutaminase (TGM2) is an important mediator of the
ligand-dependent phenotypic effects of OSMR over-expression in SCC cells. TGM2 expression correlated with
disease progression and with OSMR levels in clinical samples of cervical and oral SCC. TGM2 depletion in cervical
SCC cells abrogated OSM-induced migration on fibronectin-coated surfaces and invasiveness through extracellular
matrix, while ectopic expression of TGM2 increased cell motility and invasiveness. Confocal microscopy and co-
immunoprecipitation assays showed that TGM2 interacted with integrin–α5β1 in the presence of fibronectin in
cervical SCC cells, with OSM treatment strengthening the interaction. Importantly, integrin–α5β1 and fibronectin
were also over-expressed in cervical and oral SCC, where levels correlated with those of OSMR and TGM2.
This combined tissue and in vitro study demonstrates for the first time that stimulation of over-expressed
OSMR in cervical SCC cells activates TGM2/integrin-α5β1 interactions and induces pro-malignant changes. We
conclude that an OSMR/TGM2/integrin-α5β1/fibronectin pathway is of biological significance in cervical SCC and
a candidate for therapeutic targeting.
 2013 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great
Britain and Ireland.
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Introduction
Cervical carcinoma is the third most common cause
of cancer deaths in women worldwide. Most cases are
squamous cell carcinomas (SCCs), which arise from
precursor squamous intraepithelial lesions (SILs). Cur-
rent treatments have not changed for decades and sur-
vival rates for advanced disease remain low [1]. It is
therefore important to unravel the molecular mecha-
nisms of cervical SCC progression, in order to develop
new therapies. A key feature of cervical squamous
carcinogenesis is genomic instability, caused by dereg-
ulated expression of HPV oncogenes in proliferating
epithelial cells [2,3]. A genomic imbalance that is com-
monly selected in advanced cervical SCC is copy num-
ber gain of chromosome 5p [4,5].
One gene that is likely to drive selection of 5p
gain is the oncostatin-M receptor (OSMR; located at
5p13.1), which is commonly up-regulated in cervical
SCC and produces a significantly worse clinical out-
come when over-expressed, independent of tumour
stage [4]. As a cell surface cytokine receptor, OSMR
is a novel candidate for therapeutic targeting in cer-
vical SCC. Recently, we showed that over-expressed
OSMR enhanced the sensitivity of cervical SCC cells
to the major ligand OSM, resulting in the induction of
a pro-malignant phenotype. Direct cell effects included
increased cell migration and invasiveness, without
changes in cell proliferation [6]. Using microarrays,
we observed waves of specific gene induction over
72 h post-OSM stimulation in OSMR over-expressing
cells. The most significant Gene Ontology category
groups for the induced genes included angiogenesis,
cell invasion/migration and signal transduction. Of par-
ticular interest were the 15 genes that also showed an
association with OSMR levels in cervical SCC tissue
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samples, as identified from parallel global transcrip-
tional profiling of 29 cases [6]. These genes are listed in
our previous publication (see Supplementary material,
Table S9, in [6]). They included tissue transglutami-
nase, also known as transglutaminase 2 (TGM2).
Transglutaminases are calcium-dependent crosslink-
ing enzymes that catalyse post-translational protein
modifications. TGM2 is the most diverse and ubiqui-
tously expressed member of the family. Unlike other
transglutaminases, TGM2 is a multifunctional protein,
which has both enzymatic and non-enzymatic func-
tions. These functions are closely related to its sub-
cellular location and depend on the pathophysiological
context [7,8]. TGM2 is over-expressed in a range of
cancer types, where it is associated with metastasis
and decreased overall patient survival [9–13]. Here we
show, for the first time, that OSM–OSMR interactions
strongly induce TGM2 expression in SCC cells. The
over-expressed TGM2 interacts with integrin–α5β1 in
the presence of fibronectin and induces a promalignant
phenotype in cervical SCC cells. These in vitro find-
ings are supported by evidence from tissue samples,
that high TGM2 expression correlates with neoplastic
progression in cervical and oral squamous epithelium,




All tissue samples were used with Local Research
Ethics Committee approval. We analysed the following
tissue samples and datasets:
• Set 1 : 29 samples of cervical SCC, 32 samples
of lesional epithelium microdissected from cervical
high-grade squamous intraepithelial lesions (HSILs)
and low-grade SILs (LSILs) and 12 samples of nor-
mal ectocervical squamous epithelium, which we
previously used for microarray expression analysis
[4,6]. Raw data are available at Gene Expression
Ommibus (GEO), Accession No. GSE27678. As part
of this analysis, we studied the cervical SCCs that
showed OSMR copy number gain (n= 13), compar-
ing the cases that showed high-level OSMR over-
expression (n= 3) with those that did not (n= 10).
• Set 2 : 37 samples of cervical SCC, independent of
those in set 1, in which OSMR gene copy number
had previously been determined by tissue microarray
(TMA) fluorescence in situ hybridization (FISH) [4].
TMA sections were used for immunohistochemistry.
• Sets 3–6 : four additional datasets of cervical and
oral SCC samples with published gene expression
profiles. The samples represented 32 cervical SCC
plus 21 normal cervix (set 3) [5]; 21 cervical SCC,
seven HSIL plus 10 normal cervix (set 4) [14]; 35
oral SCC plus six normal oral mucosa (set 5) [15];
and 22 oral SCC plus five lymph node metastasis
(set 6) [16] samples. All microarray data were
obtained from the GEO database, with the Accession
Nos GSE9750, GSE7803, GSE10121 and GSE2280,
respectively.
Immunohistochemistry
Sections (5 µm) were cut onto aminopropyltriethoxy
silane-coated slides and processed for immunohisto-
chemistry, as described [17]. The primary antibody
was mouse monoclonal anti-transglutaminase 2 (Lab
Vision, Fremont, CA, USA; TG-100, IgG, 1:100).
Briefly, primary antibody (100 µl) was applied in a
humidified chamber at 4◦C overnight in 1% bovine
serum albumin (BSA) in Tris-buffered saline (TBS)
containing 0.1% Triton X-100. The slides were then
washed in TBS containing 0.025% Triton X-100 and
incubated for 1 h with biotinylated goat anti-mouse sec-
ondary antibody (1:500; Dako, Glostrup, Denmark).
A streptavidin–horseradish peroxidise (HRP) system
(Dako) with the substrate diaminobenzidine was used
to develop the stain and the slides were counterstained
with Harris’s haematoxylin. Negative controls were
performed by omitting the primary antibody. We quan-
tified the frequency of TGM2-positive cells, ie the
percentage of tumour cells that stained positively for
TGM2, regardless of intensity.
Cell culture, OSM treatment and proliferation
assays
We used the representative OSMR over-expressing cer-
vical SCC cell lines, CaSki and SW756, as well as two
non-OSMR over-expressing cervical SCC cell lines,
MS751 and ME180 [4,6]. The cells were obtained from
the American Type Culture Collection (ATCC-LGC,
Middlesex, UK) and authenticated by short tandem
repeat profiling [18]. Cell culture and OSM treatment
were performed as described [6]. OSM was added
at 10 ng/ml, in accordance with our previous studies
examining long-term effects of OSM in tissue culture
[6]. For proliferation assays, cells were trypsinized and
counted manually, using a Neubauer chamber. Dead
cells were identified with the vital stain Trypan blue
(Sigma, St. Louis, MO, USA).
TGM2 enzymatic activity assay
The crosslinking activity of TGM2 was measured
using the Specific Tissue Transglutaminase Colorimet-
ric Microassay kit (TG2-CovTest, Covalab, Cambridge,
UK), following the manufacturer’s instructions. A stan-
dard curve of purified guinea pig TGM2 (specific activ-
ity 2200 U/mg) was used to calculate the enzyme
activity in each sample.
siRNA depletion
As part of multiple complementary approaches to
minimize the possibility of non-specific observations,
cells were transfected with short interfering RNA
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(siRNA), using Lipofectamine RNAiMAX (Invitrogen,
Paisley, UK). Four TGM2-specific siRNAs (TGM2
ON-TARGETplus SMARTpool siRNA, Dharmacon,
Lafayette, CO, USA) were used in a pool at 40 nM.
Non-targeting siRNA and cyclophilin B siRNA (both
Dharmacon) were used as negative and positive
controls, respectively. The timings of OSM treatment
and transfection were optimized to maximize silenc-
ing of OSM-induced TGM2. Based on this work
(data not shown), OSM was added 6 h after siRNA
transfection.
TGM2 over-expression
We used a TGM2–pSG5 expression construct (Agilent
Technologies, Santa Clara, CA, USA), kindly provided
by Dr In-Gyu Kim, Seoul, Korea. Cells were tran-
siently transfected with 2 µg construct by nucleofec-
tion (Amaxa Nucleofector, Lonza, Basel, Switzerland),
using 1 × 106 cells/transfection for SW756 and 2 ×
106 cells/transfection for CaSki. Control transfections
were performed simultaneously, using 2 µg pmaxGFP
expression vector (Amaxa Nucleofector). We com-
pared cells expressing both TGM2 and GFP with those
expressing GFP alone.
Cell migration assay
Cells transfected with appropriate siRNAs or over-
expression constructs were plated into fibronectin-
coated two-chamber migration assay slides (Nunc,
Roskilde, Denmark) at 3 × 105 cells/chamber. After
24 h, the medium was temporarily removed and a
wound created by a gentle scratch with a sterile 200 µl
pipette tip. The cells were washed with phosphate-
buffered saline (PBS) immediately and the medium
replaced. Wound healing was monitored using time-
lapse microscopy (Axiovert Tm200, Zeiss, Thornwood,
NY, USA), with images captured every 5 min over a
period of 24 h. Average migration velocity for indi-
vidual cells in each experiment was calculated (Voloc-
ity 3D Image Analysis, Perkin-Elmer, Waltham, MA,
USA) from 30 randomly chosen cells. This number of
cells gave a statistical power> 0.95 for detecting a sig-
nificant difference (p< 0.05) between experimental and
control samples (see Supplementary material, Table S1;
http://biostat.mc.vanderbilt.edu/PowerSampleSize). All
experiments were performed in triplicate and the mean
values used to indicate migration velocities.
Cell invasion assay
Invasion assays were performed using the Cultrex
Basement Membrane Extract (BME) Cell Invasion
Assay (R&D Systems, Minneapolis, MN, USA),
following the manufacturer’s instructions; 0.5 × 106
OSM-stimulated/unstimulated control-treated or
siRNA-treated cells were seeded in the top chamber at
the start of each assay. Standard curves for each SCC
cell line were used to convert fluorescence values
into cell number. All experiments were performed in
triplicate and the mean values used to indicate invasion.
Western blotting
Whole-cell lysates were subjected to SDS–PAGE
and proteins transferred onto polyvinylidene fluoride
membranes. The following primary antibodies were
used: TGM2 (Lab Vision; 1:1600 and CST, Dan-
vers, MA, USA; 1:1000); Fak (1:1000; CST); OSMRβ
(1:500; Santa Cruz Biotechnology, Dallas, TX, USA);
integrin–α5 (1:2000), integrin–β1 (1:1000) and P-
Fak (Y397, 1:1000) (all BD Biosciences, San Jose,
CA, USA); and β-actin (1:100000; Abcam, Cambridge,
UK). Secondary HRP-conjugated antibodies (1:1000)
were from Dako. Luminograms were obtained with the
Amersham Enhanced Chemiluminescence Detection
Kit (GE Healthcare, Uppsala, Sweden) and densitome-
try performed using FluorChem-9900 imaging system
software (Alpha-Innotech, San Leandro, CA, USA).
Real-time quantitative PCR
Relative mRNA transcript levels were measured in
triplicate using QuantiTect One-Step SYBR-Green
qRT–PCR (Qiagen, Crawley, UK), following reverse
transcription of 1 µg total RNA using QuantiTect
Reverse Transcription (Qiagen). Primers were obtained
from Qiagen (Quantitect primers) or PrimerBank (see
Supplementary material, Table S2). Expression ratios
were calculated using the comparative threshold cycle
(C T) method [19] and normalized using three house-
keeping genes; ACTB , TBP and HMBS [20].
Flow cytometry
Live non-permeabilized cells detached with trypsin
were stained at 4 ◦C with anti-TGM2 (1:100; Lab
Vision) or anti-integrin–α5β1 (1:100, clone HA5; Mil-
lipore, Temecula, CA, USA) antibodies. After incuba-
tion with secondary Alexa 488 conjugated antibody
(1:100; Molecular Probes, Leiden, The Netherlands),
cells were analysed using a CyAn ADP flow cytometer
(DakoCytomation, Glostrup, Denmark). Isotypic con-
trol IgG and an appropriate fluorochrome-conjugated
secondary antibody were used in parallel as a nega-
tive control. The data were analysed using Summit 4.3
software (DakoCytomation).
Immunofluorescence staining
Cells were seeded on fibronectin-coated coverslips,
treated with OSM for 48 h and fixed using 4%
paraformaldehyde for 10 min at room temperature.
They were stained by immunofluorescence (IF) as
described [17], using an anti-TGM2 rabbit monoclonal
antibody (1:100; CST) and an anti-integrin–α5 mouse
monoclonal antibody (1:100; Abcam). Alexa 488 con-
jugated goat anti-rabbit and Alexa 594 conjugated goat
anti-mouse (1:1000; Molecular Probes) were used as
secondary antibodies, with Hoechst 33258 (Sigma)
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nuclear counterstaining. Cells were examined by con-
focal laser-scanning microscopy (Zeiss LSM 510).
Immunoprecipitation
Cells were washed with PBS and lysed in ice-cold
RIPA buffer containing 1% Triton X-100, 0.5%
sodium deoxycholate, 0.1% SDS, 150 mM NaCl,
50 mM Tris–Cl, pH 7.5, and protease and phosphatase
inhibitor cocktail tablets (Roche, Penzberg, Germany).
The lysates were incubated for 15 min at 4 ◦C on a
rotating wheel and precleared by centrifugation at 13
000 rpm for 10 min. Non-specific binding was reduced
by pre-incubating the lysates with protein G-Sepharose
(GE Healthcare) for 20 min at 4 ◦C. Total cellular pro-
tein, 1 or 2 mg (from SW756 or CaSki, respectively)
were immunoprecipitated overnight at 4 ◦C with 10 µl
anti-integrin–α5β1 antibody (clone JBS5, Millipore)
or normal mouse IgG (Millipore, used as negative con-
trol), followed by incubation with protein G-Sepharose
for a further 4 h. The complexes were harvested by cen-
trifugation, washed five times with PBS 0.1% Triton
X-100, resolved in SDS–PAGE and immunoblotted.
Pathway enrichment analysis
We performed comparative pathway analysis of two
mRNA expression datasets obtained in our previous
microarray profiling study [6]. The first set was derived
from cervical SCCs in sample set 1, that showed
OSMR copy number gain and represented genes differ-
entially expressed (p< 0.05) in the cases that showed
high-level OSMR over-expression (n= 3), compared
with those that did not (n= 10). This dataset was
determined using Affymetrix U133 Plus 2.0 arrays
(Santa Clara, CA, USA). The second set represented
genes differentially expressed (p< 0.05) in CaSki or
SW756 cells after OSM treatment, comparing cells
at 12, 24 and 48 h time points with untreated (time
0 h) cells. This dataset was determined using Human
Whole Genome 6 Expression Bead Chips v 2 (Illumina,
San Diego, CA, USA). Pathway analysis was done
using DAVID software [21,22], using platform-specific
probe IDs. Background was set as Homo sapiens to
avoid any platform bias. The categories searched were
GO_BP, KEGG_PATHWAY, BIOCARTA and BBID.
Functional annotation clusters and charts were saved
and processed with PYTHON scripts, in order to match
common information between the tissue sample and
cell line annotation clusters. Pathways were consid-
ered to be shared between the clusters if the Benjamini
adjusted p value was< 0.1 for both the tumour sam-
ples, and for either CaSki or SW756 at one or more of
the time points analysed.
Statistics
We used ANOVA, with a post hoc analysis by
the Student–Newman–Keuls’ test. Unless otherwise
stated, results are expressed as mean ± standard error
of the mean (SE).
Results
TGM2 is over-expressed and correlates with OSMR
levels in human SCCs
In our previous study of sample set 1, TGM2 was
significantly up-regulated in cervical SCC samples
with OSMR over-expression, compared with those
that lacked OSMR over-expression [6]. There was
no association between OSMR and TGM2 gene copy
number in this sample set, as assessed by comparative
genomic hybridization (data not shown). Using linear
regression analysis, we found that levels of TGM2
mRNA correlated significantly with those of OSMR
in all the set 1 SCC samples (n= 29; Figure 1A). The
frequency of TGM2 -positive cells, as determined by
immunohistochemistry, was also significantly higher
in sections of the 19 cervical SCC samples from set
2 that showed OSMR copy number gain, versus the
18 samples that lacked OSMR copy number gain
(Figure 1B).
In view of these findings, we interrogated published
data from gene expression profiling of cervical and
oral SCC (sets 3–6), as well as our cervical SILs
dataset (set 1). This showed that TGM2 expression
correlated with disease progression in cervical tissue
samples (Figure 1C, D). In set 1, TGM2 expression was
higher in SILs than in normal cervix and was signif-
icantly increased in HSILs versus LSILs (Figure 1C).
In set 3, TGM2 levels were increased in SCC sam-
ples compared to normal cervix (Figure 1D), and there
was a positive correlation between levels of TGM2
and OSMR (see Supplementary material, Figure S1A).
The correlation of TGM2 expression with disease pro-
gression was further validated in cervical sample set
4, in which expression levels increased progressively
between normal cervix, HSILs and SCCs (see Supple-
mentary material, Figure S1B).
Oral SCC samples (set 5) also showed over-
expression of TGM2 compared to normal oral mucosa,
with a positive correlation between levels of TGM2
and OSMR (Figure 1E). In an independent dataset of
oral samples (set 6), TGM2 expression was higher
in lymph node metastases than in the correspond-
ing primary tumours and in a separate set of non-
metastatic oral SCCs (see Supplementary material,
Figure S1C). Again, there was a correlation between
levels of TGM2 and OSMR in the oral SCCs and
metastases from set 6 (see Supplementary material,
Figure S1D).
OSM-induced TGM2 enhances migration and
invasion of cervical SCC cells
As the evidence from human tissue samples suggested
an important role for TGM2 in SCC progression,
we examined the functional significance of TGM2 in
cervical SCC cells in vitro. We used multiple com-
plementary experimental approaches, based on gene
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Figure 1. TGM2 expression in cervical and oral SCCs. (A) Linear regression analysis of mRNA levels of TGM2 versus OSMR in microarray
expression data for cervical SCC samples (set 1). (B) Correlation between TGM2 protein expression and OSMR copy number in cervical SCC
samples (set 2). The left-hand panels show representative images from immunohistochemical staining for TGM2 in cervical SCC samples
in which OSMR copy number gain was present (OSMR-G; top row) or absent (OSMR-N; bottom row); scale bars = 100 µm. The right-hand
box plot shows the frequency of TGM2-positive SCC cells in samples where OSMR copy number gain was present (OSMR-G) or absent
(OSMR-N): bar, median; box, IQR; whiskers, range. (C, D) Expression of TGM2 mRNA in cervical neoplastic progression. TGM2 mRNA
expression in normal cervix samples, LSILs, HSILs and SCCs was determined from microarray data derived from sample sets 1 (C) and 3 (D).
(E) Expression of TGM2 in oral SCC, based on expression microarray data for sample set 5. The left panel shows levels of TGM2 mRNA in
normal oral mucosa and oral SCC tissues, while the right panel shows linear regression analysis of TGM2 mRNA levels versus OSMR mRNA
levels in the oral SCC samples
depletion and over-expression, to minimize the possi-
bility of non-specific observations. We focused on two
representative OSMR-over-expressing cervical SCC
cell lines, SW756 and CaSki [4,6]. In both, treatment
with OSM up-regulated TGM2 at the mRNA (see Sup-
plementary material, Figure S2A) and protein levels
(Figure 2A). After 48 h of OSM treatment, levels of
TGM2 protein were induced by 360% in CaSki and by
140% in SW756 (in which basal levels of TGM2 were
high). In addition, OSM significantly induced TGM2
enzymatic activity in both cell lines, as measured by a
colorimetric assay (Figure 2B). This indicated that the
OSM-induced TGM2 was functional and catalytically
active. We observed mixed effects of exogenous OSM
in the cervical SCC cell lines that did not over-express
OSMR, MS751 and ME180 [6]. In MS751, TGM2
was induced after 24 h of OSM treatment, concomitant
with up-regulation of OSMR (see Supplementary
material, Figure S3). In contrast, in ME180 cells,
TGM2 basal levels were undetectable and there was
no induction by OSM (see Supplementary material,
Figure S3).
In both SW756 and CaSki, a single treatment
with TGM2-targeting pooled siRNAs depleted the
TGM2 induced by OSM (see Supplementary material,
Figure S4A). In our previous study [6], we found
that OSM treatment of SW756 and CaSki increased
cell migration and invasiveness but had no effect
on proliferation. In both cell lines, depletion of
TGM2 significantly reduced OSM-induced migration
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Figure 2. Effect of TGM2 depletion and over-expression on the migration and invasiveness of OSMR over-expressing cervical SCC cells.
(A) Western blot showing levels of TGM2 protein in SW756 and CaSki at 24–72 h in control cells treated with vehicle only (C) or in
OSM-treated cells (OSM). β-Actin (lower row) was used as the loading control. The graphs below each blot represent the densitometric
analysis of protein levels. Results are expressed as optical density (arbitrary units), with control cells set as 1. (B) Levels of TGM2 enzymatic
activity in SW756 and CaSki cells after 48 h in the absence (−OSM) or presence (+OSM) of OSM. (C, D) Quantification of cell migration
velocity (C) and invasiveness through basement membrane extract (D). Each panel shows data for SW756 (left column) and CaSki (right
column) following TGM2 depletion (top row) or TGM2 over-expression (bottom row). In the depletion experiments, cells were assayed after
48 h in the presence (+OSM) or absence (−OSM) of OSM. Cells with TGM2 knock-down (KD) were compared with control cells treated
with non-targeting (NT) siRNA. As background levels of TGM2 were barely detectable in CaSki (see A), TGM2 depletion was only performed
in OSM-treated CaSki cells. In the over-expression experiments, cells expressing TGM2 and GFP (GFP + TGM2) were compared with control
cells expressing GFP alone: ns, non-significant; *p< 0.05; **p< 0.01; ***p< 0.001; ****p< 0.0001
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on fibronectin-coated surfaces, as well as invasion
through extracellular matrix (Figure 2C, D, upper
panels; see also Supplementary material, Figure S5).
Conversely, ectopic TGM2 over-expression (see
Supplementary material, Figure S4B–D) significantly
increased the motility and invasiveness of both cell
lines in the absence of OSM stimulation (Figure 2C,
D, lower panels). TGM2 depletion and over-expression
had no effect on cell proliferation and viability in
the time frame of the invasion experiments (see
Supplementary material, Figure S6). Together, these
results demonstrated that TGM2 was a significant
mediator of the pro-migratory and pro-invasive
effects of OSM in OSMR over-expressing cervical
SCC cells.
TGM2 interacts with integrin–α5β1 in cervical SCC
cells in an OSM-dependent manner
Another of the 15 genes that were induced by
OSM in OSMR-over-expressing cervical SCC cells,
and also associated with OSMR over-expression in
cervical SCC tissues [6], was integrin–α5 (ITGA5).
As TGM2 has been reported to interact with
integrin–α5β1 in mesenchymal cells, leading to
binding of the cognate ligand fibronectin [23,24],
we examined interactions between OSMR, TGM2,
integrin–α5β1 and fibronectin in cervical SCC cells.
OSM increased integrin–α5 (ITGA5 ), integrin–β1
(ITGB1 ) and fibronectin (FN1 ) mRNA levels in
both SW756 and CaSki (see Supplementary mate-
rial, Figure S2). After 48 h of OSM treatment,
integrin–α5 protein levels increased 7.1- and 2.9-fold
for SW756 and CaSki, respectively (Figure 3A).
Integrin–β1 protein expression was also induced by
OSM in CaSki, with a 1.5-fold increase at 48 h. Basal
levels of integrin–β1 protein in SW756 were very
high and expression did not increase further upon
OSM treatment (Figure 3A). In the OSMR non-over-
expressing cervical SCC cells MS751 and ME180,
OSM did not induce integrin–α5 or integrin–β1 (see
Supplementary material, Figure S3).
By flow cytometry, we observed that OSM treatment
significantly increased expression of integrin–α5β1
dimers at the cell surface in both SW756 and CaSki
(Figure 3B). The function of TGM2 relates to its sub-
cellular location, with cell surface protein being respon-
sible for interactions with integrins [8]. Flow cytometry
demonstrated the presence of TGM2 on the cell sur-
face of both SW756 and CaSki (Figure 4A). OSM
treatment increased the levels of membrane-associated
TGM2, although the differences did not reach statis-
tical significance. Confocal microscopy confirmed the
cell membrane localization of TGM2 and showed focal
co-localization of TGM2 and integrin–α5 in control
and OSM-treated SW756 cells grown on fibronectin
(Figure 4B).
Immunoprecipitation with an antibody against
integrin–α5β1 confirmed that TGM2 interacted physi-
cally with integrin–α5β1 in SW756 and showed that
OSM treatment strengthened the interaction (Figure
4C left, lanes 3 and 4). In CaSki, the interaction
between TGM2 and integrin–α5β1 was only seen in
OSM-stimulated cells (Figure 4C right, lanes 3 and
4), in agreement with the very low levels of TGM2
in unstimulated (control) cells (Figure 2A). For both
cell lines, most of the TGM2 remained in the fraction
unbound by the anti-integrin–α5β1 antibody (Figure
4C, lanes 5 and 6 in both panels). This was supported
by our observation that most TGM2 is cytoplasmic
in cervical SCC cells (Figure 4B) and was consistent
with findings from mesenchymal cells [23]. In the
immunoprecipitation experiments, normal mouse IgG,
used as an isotype control, failed to pull down TGM2
and integrin–α5β1 (Figure 4C, lanes 7 and 8 in both
panels), confirming the specificity of the interaction
between TGM2 and integrin–α5β1.
We next investigated whether OSM contributed to
integrin-dependent signal transduction. In SW756 cells
cultured on fibronectin, OSM treatment increased the
levels of activated (Y397-phosphorylated) focal adhe-
sion kinase (Fak), a known early marker of integrin
activation that mediates cell adhesion, migration and
invasion [25] (Figure 4D). Levels of activated Fak
versus total Fak incresead 2.7-fold in OSM-treated
cells, compared with control-treated cells. CaSki cells
showed high basal levels of phosphorylated Fak (sim-
ilar to SiHa cervical SCC cells grown on fibronectin
[26]), which were not increased further by OSM treat-
ment (Figure 4D).
Integrin–α5β1 and fibronectin are over-expressed
and correlate with OSMR and TGM2 levels in
human SCCs
By interrogating published datasets (sets 3 and 5),
we found that integrin–α5β1 and fibronectin were
significantly over-expressed in cervical and oral SCCs
and that levels of integrin–β1 and fibronectin cor-
related with those of OSMR and TGM2 (Figure 5).
These correlations were validated in our independent
dataset of cervical SCCs (set 1), where integrin–α5
levels were also associated with OSMR expression
(see Supplementary material, Figure S7, Table S3).
In an independent dataset of oral SCCs (set 6), lev-
els of integrin–α5β1 and fibronectin again correlated
with those of OSMR, while integrin–α5 and fibronectin
levels correlated with TGM2 expression (see Supple-
mentary material, Figure S7).
Finally, we analysed pathways that were enriched
in the OSMR-over-expressing versus non-over-
expressing cervical SCCs from sample set 1, adopting
the very stringent approach used in our previous study
[6] (see Materials and methods). In total, 90 pathways
were significantly enriched. Eight of the 21 top-ranking
pathways (ranked by adjusted p value) were related
to cell migration, adhesion and extracellular matrix
(ECM) interactions (Table 1). Four of these pathways
were also enriched in OSM-treated CaSki or SW756
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Figure 3. Integrin–α5β1 expression in cervical SCC cells. (A) Western blot analysis of total levels of integrin–α5 (ITGA5) and integrin–β1
(ITGB1) in SW756 and CaSki, comparing OSM-treated cells (OSM) with control cells treated with vehicle only (C); β-actin (lower row) was
used as the loading control. (B) Flow-cytometric measurement of cell surface integrin–α5β1 in SW756 and CaSki cells, comparing cells
treated with OSM for 48 h (OSM) with control cells treated with vehicle only (C). Negative control cells were stained with an isotype
control IgG. In the graphs (bottom row) statistical comparisons were between OSM-treated and control-treated cells: **p < 0.01; ***p <
0.001
cells, compared with untreated cells. Together, these
findings further supported our evidence of associ-
ations between OSMR, TGM2, integrin–α5β1 and
fibronectin that promoted pro-malignant phenotypic
changes in cervical SCC cells.
Discussion
These combined tissue sample and in vitro data repre-
sent the first demonstration that TGM2 is an important
mediator of the ligand-dependent pro-malignant effects
of OSMR over-expression in cervical SCC cells. OSM
is a member of the IL-6 cytokine family, and is known
to signal through JAK–STAT pathways to activate
context-dependent target genes [27]. We previously
demonstrated that OSM induced STAT3 activation in
an OSMR-dependent manner in cervical SCC cells
[4], and others have shown that STAT1 and STAT5
can also be activated by OSM–OSMR binding [27].
Interestingly, there are putative STAT binding sites
in the TGM2 promoter [28]. Our data suggest that
OSM–OSMR interactions may also be responsible for
inducing TGM2 in other cell types, such as breast
cancer cells, in which OSM promotes cell motility
and metastatic behaviour and TGM2 has been associ-
ated with migration, invasion and metastasis [29–33].
In support of this, TGM2 was identified by microarray
analysis as one of the genes up-regulated in T47D
breast cancer cells after OSM treatment [34].
Our analyses of multiple independent clinical sam-
ple sets demonstrate that expression of TGM2 increases
during squamous neoplastic progression in the cervix
and oral cavity. In the cervix, levels increased between
normal cervix, SIL and SCC, while elevated levels
were also seen in oral SCC, with higher expression
in metastases compared to non-metastatic tumours.
These findings are supported by previous immunohis-
tochemical studies of clinical samples. TGM2 expres-
sion was higher in cervical SILs and SCCs than in
normal cervical squamous epithelium [35], while high
TGM2 expression in laryngeal SCC was associated
with decreased overall survival in patients treated by
surgery and radiotherapy [36].
Together, our results suggest the existence of a
biologically significant OSMR/TGM2/integrin-α5β1
pathway in cervical and oral SCC. TGM2–integrin
–fibronectin associations have previously been impli-
cated in the cell motility and invasion of breast
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Figure 4. Interactions between TGM2 and integrin–α5β1 in cervical SCC cells. (A) Flow-cytometric quantification of cell-surface TGM2
expressed by SW756 and CaSki, comparing cells treated with OSM for 48 h (OSM) with control cells treated with vehicle only (C). Negative
control cells were stained with an isotype control IgG. (B) Immunofluorescence for TGM2 (green) and integrin–α5 (red) in SW756 cells
treated with vehicle (control) or OSM (48 h) for 48 h, showing focal co-localization (yellow); scale bars = 10 µm. (C) Immunoprecipitation
showing physical interaction between TGM2 and integrin–α5β1 in SW756 and CaSki. Cells cultured on fibronectin-coated plates and
treated with vehicle (C) or OSM (OSM) for 48 h were immunoprecipitated with anti-integrin–α5β1 antibodies or with IgG isotype-matched
control antibodies. The immunoprecipitated (IP) and unbound (UNB) fractions, together with whole-cell lysates, were then analysed by
western blotting, using antibodies against TGM2 (top row), integrin–α5 (ITGA5; middle row) and integrin–β1 (ITGB1; bottom row). The
anti-integrin–α5β1 antibody precipitated TGM2 in both cell lines (cf lanes 3 and 4 versus 7 and 8 for each panel), with a stronger band
for SW756 than for CaSki. Increased levels of precipitated protein were seen in OSM-treated cells (cf lanes 4 versus 3 in each panel). (D)
Western blot showing levels of Y397-phosphorylated Fak (P-Fak) and total Fak in SW756 and CaSki cells cultured on fibronectin-coated
plates and treated with OSM or vehicle (C) for 48 h
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Figure 5. Integrin–α5β1 and fibronectin expression in cervical and oral SCCs. The panels show data derived from microarray analysis of
(A) cervical SCCs (sample set 3) and (B) oral SCCs (sample set 5). In each panel, the top row shows levels of integrin–α5 (ITGA5; left),
integrin–β1 (ITGB1; middle) and fibronectin (FN1; right) in normal mucosa and SCC tissues, while the middle and bottom rows show linear
regression analysis of expression of ITGB1 and FN1 versus OSMR (middle) or TGM2 (bottom) in the SCC samples
cancer cells [29]. While integrin–α5β1 is usually
expressed at low or undetectable levels in most adult
epithelia, it is highly up-regulated in some tumours,
including melanomas and lung carcinomas, where
high expression levels correlate with advanced disease
and reduced patient survival [37]. Integrins control
ECM remodelling, which is necessary for cancer
cell migration and invasion. Indeed, over-expression
of fibronectin and other ECM proteins has been
associated with cancer progression and metastasis
[38]. Individually, integrin–α5, fibronectin and other
ECM proteins have been shown to be over-expressed
in cervical SCC samples compared with normal
cervical epithelium [39–41]. Fibronectin and other
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Table 1. Pathways enriched in OSMR over-expressing cervical SCCs
Ranking Category term GO or KEGG ID Gene count (%) Fold enrichment Adj p
1/90 Focal adhesion hsa04510 40 3.97 2.71 1.55E-06
2/90 Cell motion∗ GO:0006928 65 6.45 2.22 3.42E-06
11/90 Biological adhesion GO:0022610 76 7.54 1.76 3.93E-04
14/90 Response to wounding∗ GO:0009611 62 6.15 1.90 4.43E-04
15/90 Cell adhesion GO:0007155 76 7.54 1.76 4.82E-04
16/90 Cell migration∗ GO:0016477 39 3.87 2.29 5.77E-04
19/90 ECM–receptor interaction hsa04512 19 1.88 3.08 2.18E-03
21/90 Cell motility∗ GO:0048870 39 3.87 2.06 5.42E-03
In total, 90 categories were significantly enriched in the OSMR over-expressing cervical SCCs from sample set 1, compared with the non-over-expressing SCCs. The
table shows the eight categories from the top 21 (ranked by adjusted p value) that supported our evidence of functionally significant interactions between OSMR and
TGM2, integrin-α5β1 and fibronectin in cervical SCC cells.
∗Pathways that were also up-regulated following OSM treatment of CaSki or SW756 cells.
Gene count, number of genes differentially expressed per category; (%), proportion of genes differentially expressed per category; Fold enrichment, ratio of the
proportion of genes from each category in the differentially expressed genes versus the proportion in all genes on the array.
ECM proteins were also up-regulated in oral SCC,
where they were associated with lymph node metas-
tasis [42]. These data reinforce our evidence that the
TGM2–integrin–α5β1–fibronectin interactions that
are activated by OSMR stimulation in SCC cells are
of biological and clinical significance.
Our findings further strengthen the interest in
antibody-based inhibition of OSM–OSMR binding as
a novel cancer therapeutic strategy. Humanized anti-
bodies against OSM are showing considerable promise
in treating rheumatoid arthritis, where they are able
to inhibit lymphocyte migration and reduce inflam-
mation [43]. Our accumulated data ([4,6] and the
present study) suggest that analogous benefits will
also be obtained in cervical SCC (and potentially
other tumour types where OSMR is over-expressed),
by reducing tumour cell migration and invasion.
It may be possible to increase therapeutic efficacy
through simultaneous targeting of other points in
the OSMR/TGM2/integrin-α5β1/fibronectin pathway.
For example, TGM2 inhibitors have been shown to
be effective in preclinical models of glioblastoma,
where they cooperated with chemotherapy in reduc-
ing tumour growth by disrupting fibronectin assembly
[44], while small molecules and antibodies targeting
integrin–α5β1 are currently being used in clinical tri-
als to block tumour angiogenesis [37]. In vivo studies
using appropriate preclinical models are now required
to test the clinical benefits of targeting this functionally
significant pathway in cervical SCC cells.
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